Classical Juvenile Pityriasis Rubra Pilaris Treated With Secukinumab: Case Report and a Review of Biological Treatments in the Pediatric Population

Pityriasis rubra pilaris (PRP) is a rare, chronic papulosquamous disorder with limited treatment options in pediatric patients. We report the case of a 9-year-old boy with juvenile PRP (type III), who achieved complete disease remission after treatment with secukinumab, an IL-17A inhibitor, following initial therapeutic resistance to topical agents. This case, notable for PRP onset after erythema infectiosum, highlights a potential infectious trigger and the therapeutic benefit of targeting the IL-17A pathway in PRP. Our findings support further exploration of secukinumab as a treatment option for juvenile PRP.